Different local estrogen therapies for a tailored approach to GSM

References

• Lachowsky M, Nappi RE. The effects of oestrogen on urogenital health. Maturitas. 2009;63(2):149–151. doi: 10.1016/j.maturitas.2009.03.012.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Polatti F. The use of estrogen therapy in women’s sexual functioning (CME). J Sex Med. 2009;6(3):603–616. quiz 618-619. doi: 10.1111/j.1743-6109.2008.01198.x.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068. doi: 10.1097/GME.0000000000000329.
   PubMed Web of Science ®Google Scholar
• Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837–847. doi: 10.1097/GME.0000000000001138.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Verde JB, Polatti F, et al. Self-reported sexual symptoms in women attending menopause clinics. Gynecol Obstet Invest. 2002;53(3):181–187. doi: 10.1159/000058371.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Albani F, Santamaria V, et al. Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas. 2010;67(1):78–83. Sep. doi: 10.1016/j.maturitas.2010.05.008.
   PubMed Web of Science ®Google Scholar
• Nappi RE. New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric. 2007;10 Suppl 2(Suppl 2):105–108. doi: 10.1080/13697130701599876.
   PubMedGoogle Scholar
• Nappi RE, Martini E, Cucinella L, et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for healthy aging in women. Front Endocrinol (Lausanne). 2019;10:561. doi: 10.3389/fendo.2019.00561.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Di Carlo C, Cucinella L, et al. Viewing symptoms associated with Vulvovaginal Atrophy (VVA)/Genitourinary syndrome of menopause (GSM) through the estro-androgenic lens - Cluster analysis of a web-based Italian survey among women over 40. Maturitas. 2020;140:72–79. doi: 10.1016/j.maturitas.2020.06.018.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Bruyniks N, et al. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause. 2019;26(5):485–491. doi: 10.1097/GME.0000000000001260.
   PubMed Web of Science ®Google Scholar
• Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215(6):704–711. doi: 10.1016/j.ajog.2016.07.045.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17(1):3–9. doi: 10.3109/13697137.2013.871696.
   PubMed Web of Science ®Google Scholar
• Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an international menopause society white paper. Climacteric. 2018;21(5):415–427. doi: 10.1080/13697137.2018.1482647.
   PubMed Web of Science ®Google Scholar
• Cucinella L, Martini E, Tiranini L, et al. Genitourinary syndrome of menopause: should we treat symptoms or signs? Curr Opin Endocr Metab Res. 2022;26:100386. doi: 10.1016/j.coemr.2022.100386.
   Google Scholar
• Nappi RE, Cucinella L, Martini E, et al. The role of hormone therapy in urogenital health after menopause. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101595. doi: 10.1016/j.beem.2021.101595.
   PubMed Web of Science ®Google Scholar
• The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American menopause society. Menopause. 2020;27(9):976–992.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Bitzer J, Cano A, et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. Maturitas. 2021;148:55–61. doi: 10.1016/j.maturitas.2021.04.005.
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Panay N, International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509–522. doi: 10.3109/13697137.2010.522875.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647–3661. doi: 10.1210/jc.2017-01138.
   PubMed Web of Science ®Google Scholar
• Shifren JL. Genitourinary syndrome of menopause. Clin Obstet Gynecol. 2018;61(3):508–516. doi: 10.1097/GRF.0000000000000380.
   PubMed Web of Science ®Google Scholar
• Phillips NA, Bachmann GA. The genitourinary syndrome of menopause. Menopause. 2021;28(5):579–588. doi: 10.1097/GME.0000000000001728.
   PubMed Web of Science ®Google Scholar
• Palacios S. Assessing symptomatic vulvar, vaginal, and lower urinary tract atrophy. Climacteric. 2019;22(4):348–351. doi: 10.1080/13697137.2019.1600499.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Mirkin S, Bernick B, et al. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361–370. doi: 10.1097/GME.0000000000001463.
   PubMed Web of Science ®Google Scholar
• Simon J, Nachtigall L, Gut R, et al. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008;112(5):1053–1060. doi: 10.1097/AOG.0b013e31818aa7c3.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017;24(4):409–416. doi: 10.1097/GME.0000000000000786.
   PubMed Web of Science ®Google Scholar
• Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010;13(3):219–227. doi: 10.3109/13697137.2010.483297.
   PubMed Web of Science ®Google Scholar
• Archer DF, Constantine GD, Simon JA, et al. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause. 2017;24(5):510–516. doi: 10.1097/GME.0000000000000790.
   PubMed Web of Science ®Google Scholar
• Simon JA, Maamari RV. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy. Climacteric. 2013;16 Suppl 1(Suppl 1):37–43. doi: 10.3109/13697137.2013.807606.
   PubMedGoogle Scholar
• Pickar JH, Amadio JM, Bernick BA, et al. Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule. Climacteric. 2016;19(2):181–187. doi: 10.3109/13697137.2015.1136926.
   PubMed Web of Science ®Google Scholar
• Cicinelli E, Di Naro E, De Ziegler D, et al. Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. Am J Obstet Gynecol. 2003;189(1):55–58. doi: 10.1067/mob.2003.341.
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJ. Are all estrogens the same? Maturitas. 2004;47(4):269–275. doi: 10.1016/j.maturitas.2003.11.009.
   PubMed Web of Science ®Google Scholar
• Delgado JL, Estevez J, Radicioni M, et al. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. Climacteric. 2016;19(2):172–180. doi: 10.3109/13697137.2015.1098609.
   PubMed Web of Science ®Google Scholar
• Rueda C, Osorio AM, Avellaneda AC, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20(4):321–330. doi: 10.1080/13697137.2017.1329291.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Ruan X, Prasauskas V, et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric. 2018;21(2):140–147. doi: 10.1080/13697137.2017.1421923.
   PubMed Web of Science ®Google Scholar
• Buchholz S, Mögele M, Lintermans A, et al. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric. 2015;18(2):252–259. doi: 10.3109/13697137.2014.991301.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause. 2020;27(5):526–534. doi: 10.1097/GME.0000000000001497.
   PubMed Web of Science ®Google Scholar
• Murina F, Graziottin A, Felice R, et al. Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule? Eur J Obstet Gynecol Reprod Biol. 2016;207:121–124. doi: 10.1016/j.ejogrb.2016.10.016.
   PubMed Web of Science ®Google Scholar
• Santos I, Clissold S. Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy. Gynecol Endocrinol. 2010;26(9):644–651. doi: 10.3109/09513591003767948.
   PubMed Web of Science ®Google Scholar
• Del Pup L, Di Francia R, Cavaliere C, et al. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients? Anticancer Drugs. 2013;24(10):989–998. doi: 10.1097/CAD.0b013e328365288e.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA. 2023;329(5):405–420. doi: 10.1001/jama.2022.24140.
   PubMed Web of Science ®Google Scholar
• Freedman M, Kaunitz AM, Reape KZ, et al. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009;16(4):735–741. doi: 10.1097/gme.0b013e318199e734.
   PubMed Web of Science ®Google Scholar
• Long CY, Liu CM, Hsu SC, et al. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause. 2006;13(5):737–743. doi: 10.1097/01.gme.0000227401.98933.0b.
   PubMed Web of Science ®Google Scholar
• Hetemäki N, Savolainen-Peltonen H, Tikkanen MJ, et al. Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women. J Clin Endocrinol Metab. 2017;102(12):4588–4595. doi: 10.1210/jc.2017-01474.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(8):CD001500.
   PubMedGoogle Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–1156. doi: 10.1097/AOG.0000000000000526.
   PubMed Web of Science ®Google Scholar
• Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–453. doi: 10.1097/GME.0000000000001221.
   PubMed Web of Science ®Google Scholar
• Palacios S, Ramirez M, Lilue M. Efficacy of low-dose vaginal 17β-estradiol versus vaginal promestriene for vulvovaginal atrophy. Climacteric. 2022;25(4):383–387. doi: 10.1080/13697137.2021.1998436.
   PubMed Web of Science ®Google Scholar
• Goetsch MF, Garg B, Lillemon J, et al. Treating where it hurts-a randomized comparative trial of vestibule estradiol for postmenopausal dyspareunia. Menopause. 2023;30(5):467–475. doi: 10.1097/GME.0000000000002162.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27(3):339–360. doi: 10.1097/GME.0000000000001468.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Graham S, Lapane K, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26(7):800–807. doi: 10.1097/GME.0000000000001315.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11–20. doi: 10.1097/GME.0000000000000956.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med. 2013;10(6):1567–1574. doi: 10.1111/jsm.12120.
   PubMed Web of Science ®Google Scholar
• Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause. 2014;21(9):911–916. doi: 10.1097/GME.0000000000000316.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018;25(6):596–608. doi: 10.1097/GME.0000000000001121.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Mension E, Torras I, et al. Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies. Climacteric. 2023;22:1–6. doi: 10.1080/13697137.2023.2184253.
   Google Scholar
• Kallak TK, Baumgart J, Göransson E, et al. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors. Menopause. 2014;21(4):383–390. doi: 10.1097/GME.0b013e31829e41df.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Murina F, Perrone G, et al. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol. 2017;69(4):370–380. doi: 10.23736/S0026-4784.17.04064-3.
   PubMedGoogle Scholar
• Reiter S. Barriers to effective treatment of vaginal atrophy with local estrogen therapy. Int J Gen Med. 2013;6:153–158. doi: 10.2147/IJGM.S43192.
   PubMedGoogle Scholar
• Nappi RE, Palacios S, Panay N, et al. The REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: country-Specific comparisons of postmenopausal women’s perceptions, experiences and needs. Maturitas. 2016;91:81–90. doi: 10.1016/j.maturitas.2016.06.010.
   PubMed Web of Science ®Google Scholar
• Mili N, Paschou SA, Armeni A, et al. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. Menopause. 2021;28(6):706–716. doi: 10.1097/GME.0000000000001752.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197. doi: 10.3109/13697137.2015.1107039.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799. doi: 10.1111/jsm.12190.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Krychman ML. The American-European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE survey. Climacteric. 2016;19(3):252–255. doi: 10.3109/13697137.2016.1173026.
   PubMed Web of Science ®Google Scholar
• Palacios S, Nappi RE, Bruyniks N, et al. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–291. doi: 10.1080/13697137.2018.1446930.
   PubMed Web of Science ®Google Scholar
• Panay N, Palacios S, Bruyniks N, et al. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas. 2019;124:55–61. doi: 10.1016/j.maturitas.2019.03.013.
   PubMed Web of Science ®Google Scholar
• Derzko CM, Röhrich S, Panay N. Does age at the start of treatment for vaginal atrophy predict response to vaginal estrogen therapy? Post hoc analysis of data from a randomized clinical trial involving 205 women treated with 10 μg estradiol vaginal tablets. Menopause. 2020;28(2):113–118. doi: 10.1097/GME.0000000000001666.
   PubMed Web of Science ®Google Scholar
• Weidlinger S, Schmutz C, Janka H, et al. Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review. Climacteric. 2021;24(6):551–559. doi: 10.1080/13697137.2021.1891218.
   PubMed Web of Science ®Google Scholar
• Palacios S, Castelo-Branco C, Currie H, et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas. 2015;82(3):308–313. doi: 10.1016/j.maturitas.2015.07.020.
   PubMed Web of Science ®Google Scholar
• Diem SJ, Guthrie KA, Mitchell CM, et al. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial. Menopause. 2018;25(10):1086–1093. doi: 10.1097/GME.0000000000001131.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Bouchard C, Pickar JH, et al. Consistency of effect with a low-dose, estradiol vaginal capsule (TX-004HR): evaluating improvement in vaginal physiology and moderate-to-severe dyspareunia in subgroups of postmenopausal women. J Womens Health (Larchmt). 2017;26(6):616–623. doi: 10.1089/jwh.2016.6187.
   PubMed Web of Science ®Google Scholar
• Caruso S, Cianci S, Vitale SG, et al. Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause. 2017;24(8):900–907. doi: 10.1097/GME.0000000000000851.
   PubMed Web of Science ®Google Scholar
• Weinberger JM, Houman J, Caron AT, et al. Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet Gynecol. 2018;132(2):453–458. doi: 10.1097/AOG.0000000000002733.
   PubMed Web of Science ®Google Scholar
• Marschalek ML, Bodner K, Kimberger O, et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. J Sex Med. 2022;19(7):1124–1130. doi: 10.1016/j.jsxm.2022.04.007.
   Web of Science ®Google Scholar
• Marschalek ML, Bodner K, Kimberger O, et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG. 2021;128(13):2200–2208. doi: 10.1111/1471-0528.16894.
   PubMed Web of Science ®Google Scholar
• Cucinella L, Martini E, Tiranini L, et al. Menopause and female sexual dysfunctions. Minerva Obstet Gynecol. 2022;74(3):234–248. doi: 10.23736/S2724-606X.22.05001-1.
   PubMedGoogle Scholar
• Ettinger B, Hait H, Reape KZ, et al. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause. 2008;15(5):885–889. doi: 10.1097/gme.0b013e318182f84b.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric. 2012;15(3):267–274. doi: 10.3109/13697137.2012.657589.
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;10(10):CD001405.
   PubMedGoogle Scholar
• Nelken RS, Ozel BZ, Leegant AR, et al. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18(9):962–966. doi: 10.1097/gme.0b013e3182104977.
   PubMed Web of Science ®Google Scholar
• Bi Y, Chen Y, Li W, et al. Experience with successful treatment of severe recurrent vulvar adhesions: a case report. Front Surg. 2023;10:1052133. doi: 10.3389/fsurg.2023.1052133.
   PubMed Web of Science ®Google Scholar